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INTRODUCTION
Multiple sclerosis (MS) is a chronic demyelinating neurological disease primarily
affecting young adults, with a prevalence of approximately 0.1% in the Caucasian
population [1]. In recent years some studies have raised concern over the possibility of
misdiagnosis in MS, which could be as high as 6%, particularly among patients with
primary progressive MS [2]. Several single gene disorders share clinical and radiologic
characteristics with MS, and have the potential to be overlooked in the differential
diagnostic evaluation of both adult and pediatric patients [2]. Diagnosis of primary
progressive MS has special challenges as there are no relapses and the MRI findings
are different from those patients with relapsing onset MS. Clinically primary
progressive MS is similar to spastic paraparesis like hereditary spastic paraparesis [3]
or other metabolic disorders, such as lysosomal storage disorders [4], mitochondrial
diseases [2] or neurometabolic disorders [5], presenting with this predominant
symptom.
MATERIAL AND METHODS
• Patients: We selected 104 patients with a presumptive diagnosis of primary
progressive MS. Blood samples were collected from these patients, from several
Portuguese hospitals, and all provided a written informed consent.
• NGS Panel Sequencing: We designed a custom panel (Suredesign - Agilent
Technologies) including 250 nuclear genes involved in mitochondrial, lysosomal,
peroxisomal and neurometabolic diseases. The coding region of these genes was
captured using SureSelect QXT kit (Agilent Technologies) and sequenced in MiSeq
Sequencer (Illumina), following the respective manufactured protocols (Figure 1).
• Data Analysis: Sequences from the FASTQ files were aligned to the human genome
(hg19) using the BWA aligner. Variant calling and annotation were performed using
available commercial programs [Surecall (Agilent) and Annovar]. Variants were filtered
taking into account the type of mutation, the population frequency, presence in
databases (dbSNP, HGMD, ClinVar, gnomAD) and in-silico predictors. After filtered, the
variants already classified as pathogenic mutations or with in-silico predictions of
possibly damaging, were confirmed by Sanger sequencing. When DNA from other
family members was available, co-segregation studies were also done.
Figure 1: SureSelect Target Enrichment workflow (Agilent)
RESULTS
For the 104 analysed samples an average of 1,484,317 reads/sample of the covered
regions was obtained by the nuclear panel and an mean read depth of 261X per
sample. On average 364 variants were detected per sample.
Variants filtered as probably pathogenic mutations were detected in of these patients
(Table 1) and confirmed by Sanger sequencing. In the remaining 97 no probably
pathogenic mutations were detected. Most of the variants found in this study were not
described in the literature.
DISCUSSION AND CONCLUSION
This study contributed to identify pathogenic mutations in 7% of the studied patients in
genes associated with hereditary spastic paraparesis and other metabolic disorders.
The uniqueness of this project is to bring NGS technology to the bedside in the
management of MS-like conditions, helping clinicians who have patients with diseases
for which a diagnosis has been elusive. Recognition of a single-gene disorder as
causal for a patient’s ‘multiple sclerosis-like’ phenotype is critically important for
effective patient management, and has broad genetic counseling implications for
affected families.
Patient Age Gene
Mutations
References
Allele 1 Allele 2
1 68Y GFAP*
p.Glu85Lys 
(c.253G>A)
-- This study
2 50Y CPT1C*
p.Glu237Lys 
(c.709G>A)
-- This study
3 42Y MFN2*
p.Leu753fs*
(c. 2258dupT)
-- [6]
4 68Y SERAC1
p.Phe47Ile
(c.139T>A)
p.Phe47Ile
(c.139T>A)
This study
5 60Y IDUA
p.Gly409Arg
(c.1225G>C)
p.Asn297Asn
(c.891C>T)
[7]; This study
6 69Y WFS1*
p.Asp118Ala
(c.353A>C)
--
[8]
7 60Y SPG7*
p.Val549Met
(c.1645G>A)
--
[9]
Table 1: Nuclear gene mutations identified in the studied patients. 
OBJECTIVES
The overall aim of our research project is to develop a Next Generation Sequencing
strategy to identify metabolic disorders in 104 patients with a presumptive diagnosis of
primary progressive MS.
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* Autosomal dominant inheritance
